Sugi Predict

Sugi Predict / Compounds / SCHEMBL2931861

SCHEMBL2931861

SCHEMBL2931861

Fc1ccc(-c2nc3[nH]ncc3c(-c3ccc(F)cc3)c2-c2ccncc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 18/20 0.48
▸ MAPK11 Q15759 6/20 0.48
▸ MAPK13 O15264 4/20 0.48
▸ MAPK12 P53778 4/20 0.48
▸ MAPK10 P53779 1/20 0.44
▸ KIT P10721 1/20 0.44
▸ GSK3B P49841 2/20 0.43
▸ CSNK1D P48730 2/20 0.43
▸ PRKD3 O94806 1/20 0.43
▸ MAP4K4 O95819 1/20 0.43
▸ FRK P42685 1/20 0.43
▸ MAPK9 P45984 1/20 0.43
▸ GCGR P47871 1/20 0.43
▸ CSNK1A1 P48729 1/20 0.43
▸ PTK6 Q13882 1/20 0.43
▸ PRKD2 Q9BZL6 1/20 0.43
▸ CLK4 Q9HAZ1 1/20 0.43
▸ EGFR P00533 1/20 0.42
▸ RAF1 P04049 1/20 0.42
▸ ADORA3 P0DMS8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29652689 1.00 MAPK14 (0.48) MAPK14MAPK11MAPK13MAPK12MAPK10
SCHEMBL1386446 0.94 MAPK14 (0.49) MAPK14MAPK11MAPK13MAPK12MAPK10
SCHEMBL1384646 0.89 MAPK14 (0.40) MAPK14MAPK11MAPK13MAPK12MAPK10
SCHEMBL2930581 0.88 POLB (0.46) MAPK14MAPK11MAPK13MAPK12MAPK10
SCHEMBL1386787 0.88 HSD17B1 (0.44) MAPK14MAPK11MAPK13MAPK12MAPK10
SCHEMBL2929925 0.87 MAPK14 (0.40) MAPK14MAPK11MAPK13MAPK12MAPK10
SCHEMBL1386922 0.86 ADORA1 (0.46) MAPK14MAPK11MAPK13MAPK12MAPK10
SCHEMBL2929750 0.86 MAPK14 (0.40) MAPK14MAPK11MAPK13MAPK12MAPK10
SCHEMBL2926060 0.86 MAPK14 (0.46) MAPK14MAPK11MAPK13MAPK12MAPK10
SCHEMBL1386721 0.86 FGFR1 (0.45) MAPK14MAPK11MAPK13MAPK12MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 — — US claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 — — EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 — — US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 — — US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 — — US claimed
US-20250011400-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA Poolbeg Pharma (UK) Limited (GB) 2025-01-09 — — US disclosed
US-12145981-B2 Methods and compounds for the treatment or prevention of severe influenza Poolbeg Pharma (UK) Limited (GB) 2024-11-19 — — US disclosed
US-20220275062-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA ORPH PHARMA IP COMPANY LIMITED (GB) 2022-09-01 — — US disclosed
US-11339207-B2 Methods and compounds for the treatment or prevention of severe influenza ORPH PHARMA IP COMPANY LIMITED (GB) 2022-05-24 — — US disclosed
EP-3478322-B1 METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA HVIVO SERVICES LTD (GB) 2020-12-30 — — EP disclosed
EP-3081568-B1 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE EIP PHARMA LLC (US) 2019-11-13 — — EP disclosed
US-9427438-B2 Compositions and methods for treating Alzheimer's disease EIP PHARMA, LLC (US) 2016-08-30 — — US disclosed
WO-2012154814-A1 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE EIP PHARMA, LLC (US) 2012-11-15 — — WO disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 — — EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 — — US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 — — US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 — — US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 — — US disclosed
EP-1611131-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach y Compagnia S.A. (ES) 2006-01-04 — — EP disclosed
WO-2004076450-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach Y Compañia S.A. (ES) 2004-09-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011400-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA CXCL10, MAPK10, MAPK1 MAPK14 15/4885MAPK11 24/4885MAPK13 20/4885
US-12145981-B2 Methods and compounds for the treatment or prevention of severe influenza CXCL10, MAPK10, CCL11 MAPK14 14/4885MAPK11 26/4885MAPK13 23/4885
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 MAPK14 34/4885MAPK11 40/4885MAPK13 36/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885MAPK11 40/4885MAPK13 37/4885
US-20220275062-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA CXCL10, MAPK10, CCL11 MAPK14 14/4885MAPK11 26/4885MAPK13 23/4885
US-11339207-B2 Methods and compounds for the treatment or prevention of severe influenza CXCL10, MAPK10, MAPK1 MAPK14 15/4885MAPK11 24/4885MAPK13 20/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885MAPK11 40/4885MAPK13 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.